iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Down 15.5% in October

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 260,100 shares, a decline of 15.5% from the October 15th total of 307,800 shares. Currently, 2.9% of the company’s shares are sold short. Based on an average trading volume of 121,300 shares, the days-to-cover ratio is currently 2.1 days.

iBio Price Performance

iBio stock traded down $0.09 during mid-day trading on Monday, hitting $2.19. The company’s stock had a trading volume of 36,825 shares, compared to its average volume of 1,172,959. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91. iBio has a 12 month low of $1.02 and a 12 month high of $6.12.

About iBio

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.